Ensign Peak Advisors’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $682K | Sell |
38,287
-850
| -2% | -$15.1K | ﹤0.01% | 1453 |
|
|
2025
Q1 | $697K | Hold |
39,137
| – | – | ﹤0.01% | 1435 |
|
|
2024
Q4 | $1.17M | Hold |
39,137
| – | – | ﹤0.01% | 1227 |
|
|
2024
Q3 | $612K | Hold |
39,137
| – | – | ﹤0.01% | 1552 |
|
|
2024
Q2 | $670K | Buy |
39,137
+2,400
| +7% | +$41.1K | ﹤0.01% | 1510 |
|
|
2024
Q1 | $574K | Sell |
36,737
-6,028
| -14% | -$94.2K | ﹤0.01% | 1589 |
|
|
2023
Q4 | $638K | Sell |
42,765
-13,630
| -24% | -$203K | ﹤0.01% | 1601 |
|
|
2023
Q3 | $911K | Buy |
56,395
+21,625
| +62% | +$349K | ﹤0.01% | 1273 |
|
|
2023
Q2 | $1.44M | Buy |
34,770
+5,280
| +18% | +$219K | ﹤0.01% | 1006 |
|
|
2023
Q1 | $1.77M | Buy |
29,490
+650
| +2% | +$39.1K | ﹤0.01% | 890 |
|
|
2022
Q4 | $2.12M | Buy |
28,840
+4,200
| +17% | +$308K | ﹤0.01% | 791 |
|
|
2022
Q3 | $1.87M | Hold |
24,640
| – | – | ﹤0.01% | 805 |
|
|
2022
Q2 | $1.71M | Hold |
24,640
| – | – | ﹤0.01% | 862 |
|
|
2022
Q1 | $2.04M | Sell |
24,640
-7,030
| -22% | -$582K | ﹤0.01% | 882 |
|
|
2021
Q4 | $2.38M | Buy |
31,670
+24,305
| +330% | +$1.82M | ﹤0.01% | 897 |
|
|
2021
Q3 | $856K | Buy |
7,365
+1,355
| +23% | +$157K | ﹤0.01% | 1484 |
|
|
2021
Q2 | $1.33M | Buy |
+6,010
| New | +$1.33M | ﹤0.01% | 1327 |
|